In silico strategies to improve insight in breast cancer

Bense, R., 2019, [Groningen]: Rijksuniversiteit Groningen. 181 p.

Research output: ThesisThesis fully internal (DIV)

Copy link to clipboard


  • Title and contents

    Final publisher's version, 608 KB, PDF document

  • Chapter 1

    Final publisher's version, 3.45 MB, PDF document

  • Chapter 2

    Final publisher's version, 3.68 MB, PDF document

  • Chapter 3

    Final publisher's version, 4.37 MB, PDF document

  • Chapter 4

    Final publisher's version, 6.06 MB, PDF document

  • Chapter 5

    Final publisher's version, 62 MB, PDF document

    Embargo ends: 20/11/2020

    Request copy

  • Chapter 6

    Final publisher's version, 3.51 MB, PDF document

  • Chapter 7

    Final publisher's version, 3.46 MB, PDF document

  • Chapter 8

    Final publisher's version, 3.46 MB, PDF document

  • Appendix

    Final publisher's version, 3.43 MB, PDF document

  • Complete thesis

    Final publisher's version, 66 MB, PDF document

    Embargo ends: 20/11/2020

    Request copy

  • Propositions

    Final publisher's version, 50 KB, PDF document


In clinical practice, breast cancer is currently divided into subtypes based on immunohistochemical expression of the estrogen receptor and human epidermal growth factor receptor 2. These subtypes are crucial for treatment choice and outcome. However, even within these subgroups there is great variability in tumor behavior. This variability within breast cancer subtypes should presumably have clinical implications for treatment decision-making and the potential of novel therapeutic targets. However, conducting trials to investigate treatment efficacy and validate diagnostics are costly, labor-intensive and time-consuming. Therefore, it takes a long time to translate the knowledge regarding tumor variability within breast cancer subtypes into clinical implications for patients. To speed up this translation, using low-cost tools for hypothesis-generation could be very convenient.

In this thesis, we used a large database of publicly available gene expression profiles as a low-cost tool to gain insight into how to improve patient selection for systemic therapy and to explore potential new therapeutic targets for difficult to treat subtypes of breast cancer. This has led to the generation of multiple hypotheses which require further study in sets of tumors from patients participating in larger prospective, preferably randomized trials. Ultimately, these findings could contribute to the further improvement of patient outcome in early-stage breast cancer.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date20-Nov-2019
Place of Publication[Groningen]
Print ISBNs978-94-034-2156-8
Electronic ISBNs978-94-034-2155-1
Publication statusPublished - 2019

Download statistics

No data available

ID: 101935267